한빛사논문 | BRIC

옥찬영 님의 논문 목록

Lunit

A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma
- Clin. Cancer Res., Mar 08 2024, | https://doi.org/10.1158/1078-0432.CCR-23-3249
- 2024-03
- 의약학
- 한빛사논문
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types
- J. Immunother. Cancer, Feb 14 2024, 12 (2) e008339 | https://doi.org/10.1136/jitc-2023-008339
- 2024-02
- 한빛사논문
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
- J. Clin. Oncol., Published online March 10, 2022 | DOI: 10.1200/JCO.21.02010
- 2022-03
- 한빛사논문
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
- Clin Cancer Res, Published May 2016 | DOI: 10.1158/1078-0432.CCR-15-2834
- 2016-05
- 의약학
- 상위피인용논문
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
- Nat. Commun., Published online: 19 October 2017, 8, Article number: 1050 | doi:10.1038/s41467-017-01018-0
- 2017-10
- 의약학
- 한빛사논문

저자논문